Evaluation of the Alere i Influenza A&B Nucleic Acid Amplification Versus Xpert Flu/RSV

April 26, 2023 updated by: Groupe Hospitalier Paris Saint Joseph

Prospective Evaluation of the Alere i Influenza A&B Nucleic Acid Amplification Versus Xpert Flu/RSV

The rapid and accurate detection of influenza virus in respiratory specimens is required for optimal management of patients with acute respiratory infections. Because of the variability of the symptoms and the numerous other causes of influenza-like illness, the diagnosis of influenza cannot be made on the basis of clinical criteria alone. Thus, rapid influenza diagnostic tests have been developed such as the Alere i Influenza A&B isothermal nucleic acid assay. Investigators prospectively evaluated the performance of the Alere i Influenza A&B assay in comparison with the routine Xpert Flu/RSV assay.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Main objective / secondary:

It appears that so far the weight of the influenza disease, the limits of clinical diagnosis and validity of rapid diagnostic methods to emergencies are well studied and validated. However the potential organizational and economic benefit in emergency care services remains little known and rarely evaluated.

The significant improvement in diagnostic response time he has a real beneficial impact for the patient? For the organization of the emergency? Investigators propose to study the impact of the implementation of rapid diagnostic solution by molecular biology of influenza directly available in an adult emergency department, from a cohort of patients consulting in connection a flu-like illness. Investigators wish in particular to highlight the organizational and economic impact.

Methodology :

DESIGN:

Study single-center, prospective, descriptive, observational, type "before / after".

Unable to reasonably perform a prospective randomized study due to the constraints for patients and for the service and means that it would be necessary to deploy in this case (CRA ... PHRC), Methodology :

DESIGN:

Study single-center, prospective, descriptive, observational, type "before / after".

Unable to reasonably perform a prospective randomized study due to the constraints for patients and for the service and means that it would be necessary to deploy in this case (CRA ... PHRC), we are moving more towards a comparison study before / after between February and April.

Time study Total study duration: 3 months Inclusion period: 3 months (February 2016- April 2016)

Acquisition of data:

Data Observing Notebook (CRF or "Case Report Form") are disclosed in the notes accompanying this document and will be collected aur an Excel spreadsheet Statistical analysis ( For each subject will be awarded an identifier (original name and surname - year of birth) and the data will be entered on a computer file which will be sent to the statistician in charge of analyzing the GHPSJ site. There will be no exchange of personal data for this study is single center on the site GHPSJ.

Development of the study:

The patient presents to the Emergency Home Service for a "flu syndrome". During the first phase ( "before"), the assumption will be that usually achieved.

During the second phase ( "after"), a flu test is routinely performed within the home emergency department by the doctor who supports the patient.

In both cases, the doctor continues to support according to information it has and according to good practice and service protocols.

A case report form (CRF or Case Report Form) is completed for each patient included in the study. This report forms includes a questionnaire that collects anonymous demographic information (patient age and sex) and clinical data. The CRF also includes the results of the rapid test for influenza. These notebooks anonymous comments are seized by the Home Emergency Service on a type of database "Access" (which will then be completed by the results of the rapid test. If positive, strain characterization will be clarified.

Number of patients recruited (justification) and duration of participation for each patient:

Not applicable as observational study are moving more towards a comparison study before / after between February and April.

Time study Total study duration: 3 months Inclusion period: 3 months (February 2016- April 2016)

Study Type

Observational

Enrollment (Actual)

92

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ile-de-France
      • Paris, Ile-de-France, France, 75014
        • Groupe hospitalier Paris saint Joseph

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

adult patients (> 18 years) consultant to the ER for influenza-like illness involving

Description

Inclusion Criteria:

  1. Respiratory Symptoms include cough, dyspnea and / or
  2. General symptoms: headache, myalgia, asthenia, anorexia ... and / or
  3. Acute fever above 38 ° C
  4. Patient consent.

Exclusion Criteria:

  • Major cognitive disorders
  • Patient under guardianship
  • Patient refusing to consent to research
  • Duplicate (patients who have had laboratory diagnosis of influenza in previous 7 days)
  • Patient not receiving social security

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group with support that will be usually performed

During the first phase ("before"), the assumption will be that usually achieved.

The doctor continues to support according to information it has and according to good practice and service protocols.

Group with a flu test

During the second phase ("after"), a flu test is routinely performed within the home emergency department by the doctor who supports the patient.

The doctor continues to support according to information it has and according to good practice and service protocols.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of change of the Length of stay in the emergency service
Time Frame: Day 1
Will be assessed with patients of the firt group (phase 1) and the second one (With Flu Test)
Day 1
Assessment of change of Hospitalization rates
Time Frame: Day 1
Will be assessed with patients of the firt group (phase 1) and the second one (With Flu Test)
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessments of change of antibiotic treatment Costs
Time Frame: Day1
Will be assessed with patients of the firt group (phase 1) and the second one (With Flu Test)
Day1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: TRABATTONI Eloïse, MD, Groupe hospitalier Paris saint Joseph

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2015

Primary Completion (Actual)

April 1, 2015

Study Completion (Actual)

April 1, 2015

Study Registration Dates

First Submitted

July 20, 2016

First Submitted That Met QC Criteria

July 22, 2016

First Posted (Estimate)

July 27, 2016

Study Record Updates

Last Update Posted (Actual)

April 27, 2023

Last Update Submitted That Met QC Criteria

April 26, 2023

Last Verified

July 1, 2016

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Influenza

Clinical Trials on Flu Test

3
Subscribe